Arena Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Arena Pharmaceuticals
Type Public (NASDAQARNA)
Industry Biotechnology
Headquarters San Diego, California, USA
Key people Jack Lief, cofounder and CEO
Dominic Behan, co-founder and senior scientist
Products in development
Revenue IncreaseUS$27.6M (FY 2012)[1]
Operating income DecreaseUS$-57M (FY 2012)[1]
Net income DecreaseUS$-85.5M (FY 2012)[1]
Total assets IncreaseUS$261M (FY 2012)[2]
Total equity IncreaseUS$98.6M (FY 2012)[2]

Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. On June 27, 2012, the FDA approved lorcaserin, initially sold under the brand name Belviq.[3] Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

As of January 2009, Arena had other experimental drugs in their pipeline that have not yet been approved by the U.S. Food and Drug Administration, namely:

See also[edit]


  1. ^ a b c Arena Pharmaceuticals (ARNA) annual SEC income statement filing via Wikinvest.
  2. ^ a b Arena Pharmaceuticals (ARNA) annual SEC balance sheet filing via Wikinvest.
  3. ^ "FDA approves Belviq to treat some overweight or obese adults" (Press release). US FDA. June 27, 2012. Retrieved January 3, 2014. 

External links[edit]